Sugi Predict

Sugi Predict / Compounds / SCHEMBL4096387

SCHEMBL4096387

SCHEMBL4096387

CC(C)N1CCC1c1cccc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.47
▸ MAOB P27338 2/20 0.43
▸ MAOA P21397 1/20 0.43
▸ GRIA4 P48058 1/20 0.40
▸ OPRK1 P41145 3/20 0.40
▸ OPRM1 P35372 2/20 0.40
▸ OPRD1 P41143 2/20 0.40
▸ OPRL1 P41146 2/20 0.40
▸ SCD5 Q86SK9 1/20 0.39
▸ LIPE Q05469 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ KDM1A O60341 1/20 0.37
▸ RCOR1 Q9UKL0 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ SLC6A9 P48067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725645 0.91 RIPK1 (0.54) RIPK1MAOBMAOAGRIA4SCD5
SCHEMBL4100913 0.91 RIPK1 (0.54) RIPK1MAOBMAOAGRIA4SCD5
SCHEMBL4106406 0.89 RIPK1 (0.50) RIPK1MAOBMAOAGRIA4SCD5
SCHEMBL4096655 0.82 RIPK1 (0.40) RIPK1MAOBMAOACYP3A4
SCHEMBL4105231 0.81 PIK3C3 (0.43) RIPK1MAOBMAOASCD5LIPE
SCHEMBL25053573 0.80 KDM4E (0.41) RIPK1MAOBMAOAGRIA4SCD5
SCHEMBL4102035 0.79 CHRNB2 (0.48) RIPK1KDM1AALDH1A1
SCHEMBL4294410 0.78 RIPK1 (0.50) RIPK1MAOBMAOALMNAALDH1A1
SCHEMBL4095055 0.77 KDM1A (0.40) RIPK1MAOBMAOAGRIA4OPRK1
SCHEMBL4096537 0.77 KDM1A (0.40) RIPK1MAOBMAOAGRIA4OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234955-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC (US) 2023-07-27 — — US disclosed
US-20230234955-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC (US) 2023-07-27 — — US disclosed
US-20210002287-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2021-01-07 — — US disclosed
US-10774085-B2 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds ARRAY BIOPHARMA INC. (US) 2020-09-15 — — US disclosed
US-10758542-B2 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-09-01 — — US disclosed
US-20190211017-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. 2019-07-11 — — US disclosed
US-20190169193-A1 Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds ARRAY BIOPHARMA INC. 2019-06-06 — — US disclosed
US-10251889-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharm Inc. (US) 2019-04-09 — — US disclosed
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2018-07-03 — — US disclosed
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds ARRAY BIOPHARMA, INC. (US) 2018-07-03 — — US disclosed
US-8865698-B2 Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds ARRAY BIOPHARMA INC. (US) 2014-10-21 — — US disclosed
US-8791123-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-07-29 — — US disclosed
US-20140194403-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC. (US) 2014-07-10 — — US disclosed
US-20130217662-A1 METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS ARRAY BIOPHARMA, INC. 2013-08-22 — — US disclosed
US-8513263-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-08-20 — — US disclosed
US-8450322-B2 Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-05-28 — — US disclosed
US-20120108568-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-05-03 — — US disclosed
US-20110195948-A1 Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors ARRAY BIOPHARMA INC. (US) 2011-08-11 — — US disclosed
US-20110166122-A1 SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2011-07-07 — — US disclosed
WO-2010048314-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011604-B2 Method of treatment using substituted imidazo[1,2b]pyridazine compounds COL2A1, COL1A1, IFNAR1 RIPK1 4526/4885MAOB 544/4885MAOA 1452/4885
US-20110195948-A1 Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors PDXK, DTYMK, TNNI3K RIPK1 321/4885MAOB 2184/4885MAOA 2906/4885
US-20190211017-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, P2RX7 RIPK1 3656/4885MAOB 1138/4885MAOA 1321/4885
US-20190169193-A1 Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds COL2A1, COL1A1, IFNAR1 RIPK1 4526/4885MAOB 544/4885MAOA 1452/4885
US-20110166122-A1 SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS NTRK1, NTRK3, NTRK2 RIPK1 452/4885MAOB 1594/4885MAOA 2818/4885
US-10251889-B2 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors TXK, FRK, LTK RIPK1 319/4885MAOB 2784/4885MAOA 3192/4885
US-20230234955-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, TK1 RIPK1 3419/4885MAOB 1939/4885MAOA 2086/4885
US-10774085-B2 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds TYMP, TYMS, P2RX7 RIPK1 3656/4885MAOB 1138/4885MAOA 1321/4885
US-20120108568-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS FRK, TXK, TNNI3K RIPK1 319/4885MAOB 2640/4885MAOA 3077/4885
US-20210002287-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS TYMP, TYMS, P2RX7 RIPK1 3656/4885MAOB 1138/4885MAOA 1321/4885
US-10758542-B2 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors LTK, TXK, FRK RIPK1 304/4885MAOB 2709/4885MAOA 3173/4885
US-20140194403-A1 METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS P2RX7, P2RX1, P2RX3 RIPK1 4415/4885MAOB 923/4885MAOA 1289/4885
US-20130217662-A1 METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS COL2A1, COL1A1, IFNAR1 RIPK1 4526/4885MAOB 544/4885MAOA 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.